Enabling value creation by empowering international companies to expand and control their new business in China.


GIBF partners with select companies from Israel, Europe and the USA to establish new JVs in the Chinese market, enabling the foreign companies to manage the new enterprises as the majority shareholders.
Based in the Greater Bay Area of South China, GIBF offers international companies the resources and expertise to create value in their JVs through multiple channels, such as expanding and expediting their global clinical trials, early entry into the Chinese market, IPO in Hong Kong under the new Biotech18-A chapter introduced by the SEHK in 2018 or similar channels planned in Chinese stock exchanges, and local M&A and licensing deals.
Unique Value Proposition
Proven Investment Model
The Parent Company provides a full IP rights for its technology for the Chinese market, know-how/expertise, as well as management
1. JV Exit: M&A or public offering in China -HKEX (Chapter 18A Hong Kong
Exchanges)
2. Conversion Mechanism: GIBF has the option to convert shares from the JV into shares of Parent Company in event of exit of Parent Company
The joint venture builds end-to-end business operations in China including R&D, manufacturing, marketing and sales

GIBF ensures successful Chinese market access with financial, regulatory, R&D, manufacturing, policy, operational and network support
Cooperate with top tier VCs in Israel and Europe, selecting targets suitable for the Chinese market.
GIBF establishes alongside international healthcare companies Joint Ventures in China and obtains the exclusive patent of China with a relatively small amount of investment